Novadaq Technologies Inc.TSX: NDQ

Novadaq Meets Key Commercialization Milestone with 50th SPY System

· Issued by Novadaq Technologies Inc. via CNW
<<
          Company Announces Patient Registry System for SPY
>>

TORONTO, July 13 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today announced
the achievement of their second commercial milestone which occurred in June
when a purchase order was received for the placement of the fiftieth SPY(R)
System in the U.S. Concurrently, the Company also announced the establishment
of the VICTORIA(TM) Multi Center Clinical Registry (Visual Interpretation of
Completeness and Technical Operative Results using Intra-operative
Arteriography) for the SPY System.
"This milestone is a significant achievement for Novadaq and represents
another step forward in the successful commercialization of our technology,"
said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq
Technologies Inc. "As well, we believe that the registry, by accumulating data
on the use of the SPY System, will help lead to the adoption of SPY as part of
the standard of care for cardiac surgery, and therefore contribute to improved
outcomes for cardiac patients in North America. We expect that these factors
will play a critical role in continuing to drive market acceptance of the SPY
System."
The East Carolina Heart Institute will be the Coordinating Center for the
Registry, which will be led by Dr. T. Bruce Ferguson, Professor and Associate
Chief, Division of Cardiothoracic and Vascular Surgery at the Brody School of
Medicine at East Carolina University. The East Carolina Heart Institute, a
joint venture between the State of North Carolina, the Brody School of
Medicine at East Carolina University and University Health Systems of Eastern
Carolina, is devoted specifically and exclusively to the research, treatment
and prevention of cardiovascular diseases.
"This registry is very unique in its scope," said Dr. Ferguson. "The
imaging and clinical data we will collect will be from 1500 coronary artery
bypass patients and an estimated 9000 revascularization images, and has the
potential to establish a new standard of care and quality in cardiac
revascularization."

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery, LUNATM
is being developed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

Certain matters discussed in this release could constitute
forward-looking information that is subject to risks and uncertainties
relating to Novadaq's future financial or business performance. Actual results
could differ materially from those anticipated by this forward-looking
information. Forward-looking information may relate to management's future
outlook and anticipated events or results, and may include statements or
information regarding the future financial position, business strategy and
strategic goals, research and development activities, projected costs and
capital expenditures, financial results, research and clinical testing
outcomes, taxes and plans and objectives of or involving Novadaq, or
statements or information relating to market acceptance of, and use of, the
SPY System. Particularly, information regarding future sales and marketing
activities, future revenues and research and development activities, expected
acceptance and use of the SPY System, as well as the Company's plans for each
of the SPY System, OPTTX System and LUNA System, is forward-looking
information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, market acceptance and the rate of market
penetration of Novadaq's SPY System, the clinical results of the use of the
SPY System, the results from clinical tests of the OPTTX System, and potential
opportunities in the AMD treatment market and in image guided conventional and
minimally invasive urological applications including nerve-sparing radical
prostatectomy. While the Company considers these assumptions to be reasonable
based on information currently available to it, they may prove to be
incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System, dependence on key suppliers
for components of the SPY System and the OPTTX System, regulatory and clinical
risks, risks relating to the protection of intellectual property, risks
inherent in the conduct of research and development activities, including the
risk of unfavorable or inconclusive clinical trial outcomes, potential product
liability, competition and the risks posed by potential technological
advances, and risks relating to fluctuations in the exchange rate between the
US dollar and the Canadian dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases